Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.

Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U

The Journal of the Association of Physicians of India1 Jun 2008Cited by 15 (Europe PMC)

PMID18822620PepBankPUB-18822620

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, lumbar spine BMD increased more with teriparatide than control, 6.58% versus 1.06%.
In plain wordsIn women with osteoporosis, spine bone density increased more with teriparatide than control, 6.58% versus 1.06%.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n: not reported in source
Comparator
Control with calcium and vitamin D
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Lumbar spine BMD increase
6.58%
teriparatide
Lumbar spine BMD increase
1.06%
control
Source sentences
Summary
The percentage of increase in lumbar spine BMD, which is the primary endpoint, was significantly (P < 0.001) higher in teriparatide group compared to that in control group (6.58% vs. 1.06%).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients.
Summary · context
Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously.
Report a problemFND-1882262006
02HumanRandomized controlled trialSafety outcome
In women with osteoporosis, no serious adverse events occurred with teriparatide.
In plain wordsIn women with osteoporosis, no serious adverse events occurred with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSerious adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
The investigational product teriparatide was well tolerated and there were no serious adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients.
Summary · context
Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously.
Report a problemFND-1882262004
03HumanRandomized controlled trialSafety outcome
In women with osteoporosis, adverse event incidence did not differ significantly between teriparatide and control groups.
In plain wordsIn women with osteoporosis, adverse event rates did not differ significantly between teriparatide and control groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAdverse event incidence
Study
n: not reported in source
Comparator
Control with calcium and vitamin D
Outcome group
Adverse events · Whole body
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
In addition, there were no significant differences between the groups in the incidence of adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients.
Summary · context
Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously.
Report a problemFND-1882262005
04HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide increased lumbar spine T-score percentage change more than control.
In plain wordsIn women with osteoporosis, teriparatide improved the spine T-score percentage change more than control.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine T-score
Study
n: not reported in source
Comparator
Control with calcium and vitamin D
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Further, teriparatide significantly increased percentage of change in lumbar spine T-score (P < 0.001), BMC (P < 0.001) and bone area (P < 0.028) compared to control group at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients.
Summary · context
Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously.
Report a problemFND-1882262007
05HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide increased lumbar spine BMC percentage change more than control.
In plain wordsIn women with osteoporosis, teriparatide increased spine bone mineral content more than control.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMC
Study
n: not reported in source
Comparator
Control with calcium and vitamin D
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Further, teriparatide significantly increased percentage of change in lumbar spine T-score (P < 0.001), BMC (P < 0.001) and bone area (P < 0.028) compared to control group at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients.
Summary · context
Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously.
Report a problemFND-1882262008
06HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide increased lumbar spine bone area percentage change more than control.
In plain wordsIn women with osteoporosis, teriparatide increased spine bone area more than control.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine bone area
Study
n: not reported in source
Comparator
Control with calcium and vitamin D
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Further, teriparatide significantly increased percentage of change in lumbar spine T-score (P < 0.001), BMC (P < 0.001) and bone area (P < 0.028) compared to control group at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients.
Summary · context
Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously.
Report a problemFND-1882262009
07HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide increased BSAP more than control at 3 and 6 months relative to baseline.
In plain wordsIn women with osteoporosis, teriparatide increased the BSAP bone marker more than control at 3 and 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBSAP
Study
n: not reported in source
Comparator
Control with calcium and vitamin D
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Administration of teriparatide resulted in a significant percentage of increase in all the bone biomarkers in teriparatide group compared to control group patients at 3 and 6 months over baseline,
3 context sentences(design, population, supporting numbers)
Summary · context
Bone biomarkers, such as serum bone specific alkaline phosphatase (BSAP) and serum osteocalcin (OC), representing bone formation, and urinary deoxypyridinoline (DPD), representing bone resorption were assessed at baseline, and at 3 and 6 months of treatment.
Summary · context
A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients.
Summary · context
Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously.
Report a problemFND-1882262010
08HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide increased osteocalcin more than control at 3 and 6 months relative to baseline.
In plain wordsIn women with osteoporosis, teriparatide increased osteocalcin more than control at 3 and 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseOsteocalcin
Study
n: not reported in source
Comparator
Control with calcium and vitamin D
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Administration of teriparatide resulted in a significant percentage of increase in all the bone biomarkers in teriparatide group compared to control group patients at 3 and 6 months over baseline,
3 context sentences(design, population, supporting numbers)
Summary · context
Bone biomarkers, such as serum bone specific alkaline phosphatase (BSAP) and serum osteocalcin (OC), representing bone formation, and urinary deoxypyridinoline (DPD), representing bone resorption were assessed at baseline, and at 3 and 6 months of treatment.
Summary · context
A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients.
Summary · context
Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously.
Report a problemFND-1882262011
09HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide increased urinary DPD more than control at 3 and 6 months relative to baseline.
In plain wordsIn women with osteoporosis, teriparatide increased urinary DPD more than control at 3 and 6 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUrinary DPD
Study
n: not reported in source
Comparator
Control with calcium and vitamin D
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Administration of teriparatide resulted in a significant percentage of increase in all the bone biomarkers in teriparatide group compared to control group patients at 3 and 6 months over baseline,
3 context sentences(design, population, supporting numbers)
Summary · context
Bone biomarkers, such as serum bone specific alkaline phosphatase (BSAP) and serum osteocalcin (OC), representing bone formation, and urinary deoxypyridinoline (DPD), representing bone resorption were assessed at baseline, and at 3 and 6 months of treatment.
Summary · context
A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients.
Summary · context
Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously.
Report a problemFND-1882262012

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00500409

Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis

Virchow Groupn = 82Dec 2005 to Jul 2007

Osteoporosis

Trial page ClinicalTrials.govUpdated 16 Dec 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.